Testimonials

Professional, timely, friendly, collaborative communication/partnering to generate a high quality report to support our NDA filing. As expected from the staff at XenoTech. Jennifer Horkman did a fantastic job leading the effort.

Pharmaceutical Senior Research Scientist

Great reports that are ready for submission to the Agency!

Pharma Senior Vice President of R&D

Thanks again to you and the team for your tremendous efforts in getting this study completed. It has been a pleasure and we look forward to working with you again in the near future.

I am joining in warmly thanking you again for your hard work in this important study. Indeed this analyte posed its very own set of challenges, but your openness to discussion and changes, as well as your deeply scientific approach made the entire process productive and really worth it. We are looking forward to more collaboration!

Pharma DMPK/Bioanalytical Senior Manager with Associate Director

It was a blast working with Jennifer Horkman. Having more experienced scientific staff like Lois Haupt and Joanna Barbara available ‘on-call’ when needed works well for me. We had a tight timeline that shifted (like they always do). In these situations, my view is that the sponsor shares responsibility for those timelines and I found it easy to work with XT Study Directors on meeting the timelines effectively. It’s difficult to have a sponsor’s context on the design of the project because sponsors (purposefully) do not provide all of the information about the program. Given the information we made available to XT, XT provided a good study design. I had a hard time finding any comments on the reports. They were tight and the data were clear.

Pharma Principal Scientist

I have long favored the subcellular fractions that XenoTech offers over the competition.

Pharmaceutical Development Research Scientist

Very pleased with the technical assistance during protocol design, provided by the Xenotech team. Next steps and follow up were provided as a separate analysis, not as part of the report itself, but the report provided the necessary basis for the analysis.

Associate Director for a Rare Diseases Pharma

I appreciate the calculations that XenoTech did for us based on the FDA DDI Guidance. I also appreciate the 2 teleconferences that we had with the study director and Lois Haupt that helped us to understand the data.

Biotech Executive Director

Our experiments went fantastically well – we see some potential in the material as a tool to generate metabolites of interest in higher yields than the typical systems. See attached a snapshot of one experiment where we incubated a X compound in development with Hepatocytes, Microsomes and the Lysosomes you provided us with. With Lysosomes we were able to generate a metabolite (M6) with significantly higher yields and this is great because it may be a useful tool to allow full characterization of metabolites.

From a Customer of our EU Partner, tebu-bio